Breast Cancer Research and Treatment **63:** 261–262, 2000.
© 2000 *Kluwer Academic Publishers. Printed in the Netherlands.*

Authors Index, Volume 63

Adessi GL 163
Agrup M 23
Algros M-P 163
Amadori D 181

Bajorko P 181
Balzi M 181
Bamberger A-M 243
Baron M-H 163
Bartels KCM 53
Basu M 133
Becciolini A 181
Bendall LJ 105
Bermont L 163
Bishayee A 133
Bonilla F 17
Bradstock KF 105
Brudin L 11

Chatterjee M 133
Chaudhry M 1
Cheng JC-H 213
Cheng SH 213
Chi KN 199
Choe KJ 81
Cornélissen G 171
Cullen KJ 95

de Menezes DL 199
Depisch D 235
Diel P 249
Dominguez G 17
Dragowska WH 199

España P 17

Fan S 147
Feng F 71

Garcia JM 17
Garmroudi F 95
Gewirtz DA 1
Goldberg ID 147
Gottlieb DJ 105
Granato AM 181
Gupta M 1

Hafer LJ 117
Haider K 235
Halberg F 171
Holli K 225
Hsieh C-Y 213
Huang AT 213

Imoto S 31
Iwata H 31

James A 105
Jareño E 17
Jian JJ 213
Joensuu H 225

Kang H-S 81
Katinas G 171
Kim DW 117
de Koning HJ 53
Kornek G 235
Kubista E 95
Kurosumi M 31
Kwasny W 235

Lang F 235
Lee CH 199
Leu S-Y 213
Löffek S 249
Liu M-C 213
Luo J 61

Mayer LD 199
Maskarinec G 153
Matulka RA 117
Meng L 153
Meng Q 147
Michna H 249
Migaldi M 193
Miller MW 61
Miralles C 17
Miyauchi M 31
Mizejewski GJ 41
Motomura K 31

Nanni O 181
Near RI 117
Nicoll JAR 193
Noguchi M 31
Noh D-Y 81
Nordenskjöld B 11

Obdeijn IMM 53
Oh S-K 81
Ohta M 31
Oinam S 133
Oksanen H 225
Olsen K 23
Oudkerk M 53

Paola FD 181
Penz M 235
Provencio M 17

Reardon D 1
Riccobon A 181
Rittling SR 71
Rodriguez O 17
Rogers AE 117
Rosen EM 147

Saad S 105
Sartor J 199
Sato K 31
Scarpi E 181
Scheithauer W 235
Schulte HM 243
Schulz T 249
Sherr DH 117
Silva JM 17
Simpson HW 171
Singer CF 95
Smolnikar K 249

Sonenshein GE 117
Stål O 11, 23
Sundaram S 1
Sundquist M 11

Thorstenson S 11
Thuneke I 243
Tilanus-Linthorst MMA 53
Toselli PA 117
Trentini G-P 193
Trombino AF 117
Tsou M-H 213
Tsugawa K 31

Ulrich-Pur H 235

Vakharia D 41
Valavaara R 225
Valencak J 235
Volpi A 181

Wallis AE 199
Wingren S 23

Yang S 117
Youn Y-K 81

Zunarelli E 193

Breast Cancer Research and Treatment **63:** 263–266, 2000.
© 2000 *Kluwer Academic Publishers. Printed in the Netherlands.*

Subject index, Volume 63

adriamycin
  antiproliferative effects in MCF-7 breast tumor cells 1-10
  apoptotic effects in MCF-7 breast tumor cells 1-10
  as a treatment for MCF-7 breast tumor cells 1-10
  in combination with EB1089 1-10
advanced breast cancer
  treatment with alternating docetaxel 235-241
AFP-peptides
  binding estrogen receptor and estradiol 41-52
  suppresive growth properties 41-52
AhR hyperexpression
  in rat breast tumors 117-131
allelic loss
  in the *p73 gene* region 17-22
alpha fetoprotein
  modified by estrogons to exhibit growth suppressive properties 41-52
alternating docetaxel and EC + G-GCS
  as a treatment for advanced breast cancer 235-241
antiestrogens
  inducing TNFR1 in MCF-7 breast cancer cells 249-259
antineoplastic agents
  control of apoptosis arising from exposure 199-212
anti-sense oligonucleotides
  blocking ethanol-induced chemo-migration 61-69
  effects on human breast cancer cells 199-212
  eliminating heregulin B1?-promoted migration 61-69
APOE polymorphism, *see* apolipoprotein E polymorphism
apolipoprotein E polymorphism
  relation to breast carcinoma 193-198
  relation to variation in the rate of tumor cell proliferation 193-198
apoptosis
  control during exposure to anticancer agents 199-212
  induction by faslodex 249-259
  of adriamycin in MCF-7 breast tumor cells 1-10
aryl hydrocarbon receptor, *see* AhR
axillary lymph node dissection
  identification with SLN biopsy 31-40

Bcl-2 modulation
  in combination with G3139 antisense oligonucleotide 199-212
  regulating apoptosis in breast cancer cells 199-212
biological markers
  prognostic significance in node-negative breast cancer 181-192
biphasic effects
  of MPA treatment on proliferation in T47D breast cancer cells 243-248
bone marrow fibroblasts
  induction of MMP-1 and MMP-2 by co-culture with breast cancer cells 105-115
breast neoplasm
  marked by mammographic densities 153-161
breast surface temperature
  changes associated with the luteal cycle 171-173
breast tumors
  expression of AhR and *CYP1* 117-131
  relation with APOE polymorphism 193-198
  relevance of p185 expression 163-169
  screening with MR imaging 53-60
  treatment witf faslodex 249-259
  unique features of patients in Taiwan 213-223

case-control study
  of mammographic densities in Hawaii 153-161
c-erbB-2 amplification
  association with p185 overexpression 163-169
  correlation with aggressive breast cancers 163-169
  in early onset breast cancer 23-29
chemoprevention
  by vanadium 133-145
  in mammary carcinogenesis 133-145
chemosensitization
  and the expression of Bcl-2 199-212
chemotherapy
  role in the treatment of advanced breast cancer 235-241

cholesterol
  decrease of serum level by tamoxifen 225-234
clinical outcome
  correlation with APOE polymorphism and breast carcinoma 193-198
cyclin D1
  Biphasic effects of MPA treatment 243-248
cyclophosphamide
  alternating with docetaxel as a treatment for advanced breast cancer 235-241
CYP1
  AhR-regulated transcripts in rat breast tumors 117-131
  hyperexpression in rat breast tumors 117-131

database
  of early-onset breast cancer in Taiwan 213-223
docetaxel
  alternating with EC + G-GCS as a treatment for advanced breast cancer 235-241

early onset breast cancer
  C-erbB-2 overexpression 23-29
  prognostic factors 23-29
EB 1089
  enhancement of antiproliferative and apoptotic effect of adriamycin 1-10
  exposure of MCF-7 breast tumor cells 1-10
E-cadherin
  upregulation through inhibitory effects of Indole-3-carbinol 147-152
EC + G-GCS alternating with docetaxel
  as a treatment for advanced breast cancer 235-241
epidermal growth factors
  unaffected by ethanol-enhanced migration of human breast cancer cells 61-69
epirubicin
  alternating with docetaxel as a treatment for advanced breast cancer 235-241
estradiol
  bound by AFP-peptides 41-52
  suppressive growth properties 41-52
estrogen receptor
  bound by AFP-peptides 41-52
  suppressive growth properties 41-52
ethanol
  enhances erbB-mediated migration of human breast cancer cells 61-69
ethnicity
  differences in incidence for breast cancer 153-162
  erbB-mediated migration enhanced by ethanol 61-69
  of human breast cancer cells 61-69

faslodex
  TNFR induction in MCF-7 breast cancer cells 249-259
familial risks
  for breast cancer 53-60
feedback mechanisms
  in human breast cancer 95-104
flow cytometry
  in metastatic nodes in breast cancer 81-87

G-CSF
  alternating with docetaxel as a treatment for advanced breast cancer 235-241
gene knockout
  in OPN −/− mice 71-79
glutathione
  level reducement through vanadium 133-145
growth factor receptors
  enhanced by ethanol in human breast cancer cells 61-69
G3139 antisense oligonucleotide
  effects on human breast cancer cells 199-212
  in combination with Bcl-2 modulation 199-212

Hawaii
  incidence of mammographic densities 153-161
HER-2/neu
  overexpression in early onset breast cancer 23-29
  heregulin-mediated invasion 61-69
high-grade malignancy
  clinicopathological characteristics 17-22
human breast cancer cells
  erbB-mediated migration 61-69
human breast tissue
  Luteal-cycle associated changes 171-173

ICI 182780
  inducing TNFR1 in MCF-7 breast cancer cells 249-259
immunohistochemistry
  its role in the decreased survival rate of young breast cancer patients 23-29
Indole-3-carbinol
  inhibitory effects on human breast cancer cells 147-152
  role in chemoprevention of breast cancer 147-152
inhibition

effect of Indole-3-carbinol 147-152
of mammary carcinogenesis by vanadium 133-145
invasion
inhibitory effect of Indole-3-carbinol 147-152
in human breast cancer cells 147-152

local feedback mechanisms
in human breast cancer 95-104
LOH, *see* loss of zygosity
loss of zygosity
in the *p73 gene* region 17-22
Luteal cycle
associated changes in human breast tissue 171-173

magnetic resonance imaging, *see* MR imaging
mammary carcinogenesis
inhibition by vanadium 133-145
involvement of phase I and II enzymes 133-145
mammary tumorigenesis
in OPN −/− mice 71-79
mammographic density
as markers for breast cancer risk 153-161
case-control study in Hawaii 153-161
matrix metalloproteinases, *see* MMP
MCF-7 breast tumor cells
antiproliferative effects of adriamycin 1-10
apoptotic effects of adriamycin 1-10
exposure to the vitamin D analog EB 1089 1-10
inducing TNFR1 expression 249-259
treatment with faslodex 249-259
metastatic nodes in breast cancer
flow cytometry 81-87
metastasis
enhanced by ethanol by altering an erB system 61-69
migration
inhibitory effect of Indole-3-carbinol 147-152
in human breast cancer cells 147-152
throught bone marrow fibroblasts 105-115
MMP-1
induction by co-culture of breast cancer cells and bone marrow fibroblasts 105-115
MMP-2
induction by co-culture of breast cancer cells and bone marrow fibroblasts 105-115
MPA treatment
biphasic effect on proliferation in T47D breast cancer cells 243-248
MR imaging
screening women for breast cancer 53-60
multicenter validtion study
of sentinel lymph node biopsy 31-40

node-negative breast cancer
prognostic significance of biological markers 181-192
Nottingham histologic grade
as a prognostic instrument in breast cancer 11-15

OPN −/− mice
mammary tumorigenesis development 71-79
osteopontin
disruption in OPN −/− mice 71-79
high levels in mammary tumors 71-79

paracrine regulation
within a malignant tumor 95-104
peptides
modified to exhibit suppressive growth properties 41-52
p185 overexpression
associated with *c-erbB-2* amplification 163-169
correlation with poor prognostic factors 163-169
relevance for human breast carcinoma 163-169
prognostic factors
biological markers 181-192
c-erbB-2 amplification 163-169
for patients with node-negative breast cancer 181-192
for patients with early-onset breast cancer in Taiwan 213-223
in breast cancer 11
in early onset breast cancer 23-29
of S-phase fraction in breast cancer 11-15
of Nottingham histologic grade in breast cancer 11-15
p185 overexpression 163-169
young age 23-29
proliferation
biphasic effects of MPA treatment 243-248
p73 gene
allelic loss 17-22
clinicopathological characteristics of high-grade malignancy 17-22
PTEN
up-regulation through inhibitory effects of Indole-3-carbinol 147-152

ras
expressed by OPN −/− mice 71-79

rat liver
anticarcinogenic activity of vanadium 133-145
risk factors
for developing breast cancers 153-161

screening
of women at high risk for breast cancer 53-60
with MR imaging 53-60
second-line
docetaxel in combination with EC + G-GCS as a treatment for advanced breast cancer 235-241
sentinel lymph node biopsy
as a means to identify axillary lymph node metastase 31-40
serum lipids
as a therapy for breast cancer 225-234
in combination with tamoxifen and toremifene 225-234
S-phase fraction
as a prognostic instrument in breast cancer 11-15
7,12-dimethylbenz(a)anthracene
-induced mammary carcinogenesis 133-145
signal transduction
influence of ethanol 61-69

Taiwan
unique features of patients with breast cancer 213-223
tamoxifen
as a therapy for breast cancer 225-234
in combination with toremifene and serum lipids 225-234
TNFR1 induction
by faslodex in breast cancer cells 249-259
toremifene
as a therapy for breast cancer 225-234
in combination with tamoxifen and serum lipids 225-234
transgenic mice
mammary tumorigeneses development 71-79
triglycerides
increase of serum level by tamoxifen 225-234
tumorigenesis
AhR-regulated CYP! gene transcripts 117-131
in OPN −/− mice 71-79
T47D breast cancer cells
biphasic effects of MPA treatment 243-248

vanadium
as a antitumor agent 133-145
as a protection against DMBA-induced mammary carcinogenesis 133-145
inhibition of mammary carcinogenesis 133-145
vitamin D
enhancement of antiproliferative and apoptotic effect of adriamycin 1-10
exposure of MCF-7 breast tumor cells 1-10

young age
as a prognostic factor in early onset breast cancer 23-29
of patients with breast cancer in Taiwan 213-223